Peony of Your Thoughts: May Bring Advances to Alzheimer’s Disease Research

May was useful for the prevention and diagnosis of Alzheimer’s disease, the mechanisms behind the initial symptoms, and the study of potential therapies to prevent the symptoms that appear later in the disease’s progression.

Phase IIA clinical trial of Alzamend Neuro for the treatment of dementia

The first dose is given to the participants Phase IIA study Investigate the safety and maximum tolerability of Alzamend’s AL001. Treatment candidates feature a proprietary prescription delivery system for lithium-salicylic acid-L-proline.

The study design includes 12 months of treatment with multiple escalating dose schedules. Bioisostere data from Phase I studies suggest that sufficient evidence may be available to avoid the need for Phase II and III studies demonstrating safety in a larger pool of participants. I am. Instead, safety has been demonstrated by a match of bioequivalent lithium carbonate that has already been approved by the regulatory agency.

new In vitro Test for diagnosis

The US Food and Drug Administration (FDA) gave Approval for commercialization Results of the Lumipulse Gβ-amyloid ratio (1-42 / 1-40) test. It was previously given a breakthrough device designation. This test is intended for patients over the age of 55 who have clinical symptoms of Alzheimer’s disease. Using a sample of cerebrospinal fluid, doctors can receive data for the day without exposing the patient to high-level PET scans.

Physicians are expected to use Lumipulse test data in combination with other means of confirming the diagnosis of Alzheimer’s disease.

Potential targets revealed to reduce indifference

Alzheimer’s disease causes the brain to slowly degenerate, so psychiatric symptoms and decreased cognitive function can manifest as personality changes such as the development of apathy.Research published in Molecular psychiatry suggestion The onset of apathy may be associated with the development of dysregulation of the neurotransmitter glutamate in the nucleus accumbens region of the brain. True, glutamate can be pharmacokinically blocked by medication and prevent or delay psychiatric changes.

Good Cholesterol and Alzheimer’s Disease

Article published by Alzheimer’s Association He explains that high-density lipoprotein cholesterol (HDL-C) levels can affect the risk of people who develop Alzheimer’s disease. Dr. Hussein Yasin, MD, explains that HDL particles “may be involved in the clearance and excretion of the peptides that form the amyloid plaques found in Alzheimer’s disease.”

This study is motivated by finding ways to prevent cardiovascular problems that often cause Alzheimer’s disease, such as smoking and the harm caused by high blood pressure. Physicians can now confidently advise patients that high levels of HDL-C may reduce their risk of developing neurodegenerative disease. Anyone who wants to raise HDL levels should focus on general health promotion activities such as exercise, a healthy diet, and minimizing alcohol intake.

Beneficial dietary supplements or harmful gimmicks?

A study Implemented by University of California, San Diego Researchers investigating the role of the phosphoglycerate dehydrogenase (PHGDG) enzyme in the development of Alzheimer’s disease warned patients to avoid certain supplements.

The PHGDG enzyme is involved in the production of serin, an amino acid that is naturally present in the human body. Serine supplements are often taken with the belief that patients with Alzheimer’s disease will benefit. The study found that patients with Alzheimer’s disease already had higher levels of PHGDG than those with typical development, and concluded that serin supplementation could cause harm.

Two proteins associated with Alzheimer’s disease

Massachusetts General Hospital Have Conduct a survey It may explain how the brain responds to protein accumulation in the role played by amyloid β and tau protein in patients with Alzheimer’s disease. This study included analysis of PET and MRI images from more than 6,000 patients in a single family. This family had a high prevalence of Alzheimer’s disease.

Analysis revealed an association between developing Alzheimer’s disease and high levels of amyloid-β almost 20 years before the onset of cognitive symptoms, as indicated by the presenilin-1 E280A mutation. This study helps to understand the mechanism of early dementia.

Corn protein may be key to Alzheimer’s disease vaccine

Researcher University of Kansas It is possible that they have found a way to elicit an immune response in patients with the characteristic beta-amyloid plaques found in Alzheimer’s disease. The idea of ​​using a vaccine to prevent plaque buildup to boost immunity to Alzheimer’s disease is not new, but those who thought that corn may contain methionine sulfoxide, an important component of the vaccine. Is almost nonexistent.

To study this hypothesis, we used a mouse model to determine whether injection of methionine-sulfoxide-rich antigens affected the development of Alzheimer’s disease compared to mice that were not engineered with a predisposition to Alzheimer’s disease. I decided. Overall, the mouse group showed “about 50% improvement in short-term memory, better long-term memory, and low levels of plasma and brain beta-amyloid.” The immune system and antioxidant activity also increased in the group.